Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $1.92M (cash outflow) rose 171.1% year over year, ahead of the +117.3% change in trailing-twelve-month net income. Sequentially, it fell 24.4% from the prior quarter. Over 3 fiscal years it compounded at -1.6% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +171.1% holds above the trailing-twelve-month pace of +117.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (6.01M) USD
- Year-over-year change
- -67.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.01M) | -67.6% |
| FY2024 | 2024-12-31 | (3.59M) | +29.5% |
| FY2023 | 2023-12-31 | (5.09M) | +19.4% |
| FY2022 | 2022-12-31 | (6.31M) | +6.2% |
| FY2021 | 2021-12-31 | (6.73M) | — |
Net Income vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's LTM Mar 2026 net income of $7.22M is the smallest of the 2 companies compared; the peer median is $27.71M.
- Its year-over-year change of +117.3% is the highest of 2, against a peer median of +69.2%.
- Over three fiscal years its annual growth of -1.6% compares with a peer median of +8.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $27.71M | +69.2% | +8.3% | — | |
| LTM Mar 2026 | $7.22M | +117.3% | -1.6% | — | |
| Peer median (excluding LIXT) | $27.71M | +69.2% | +8.3% | — | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.